Search information pages
About Experimental Hematology and Oncology
This page includes information about the aims and scope of Experimental Hematology and Oncology, editorial policies, open access and article-processing charges, the peer review process and other information. For details of how to prepare and submit a manuscript through the online submission system, please see the instructions for authors.
Aims & scope
Experimental Hematology & Oncology is an open access, peer-reviewed online journal that encompasses all aspects of hematology and oncology with emphasis on preclinical, basic, patient-oriented and translational research. The journal acts as an international platform for sharing laboratory findings in these areas and makes a deliberate effort to publish clinical trials with "negative" or preliminary results and basic science studies with provocative findings.
Experimental Hematology & Oncology aims to publish original work, hypothesis, commentaries and timely reviews in the closely related fields of hematology and oncology.
With open access, rapid turnaround time from submission to publication and online live comments from readers, Experimental Hematology & Oncology will strive to be the hub for disseminating new knowledge and discussing controversial topics for both basic scientists and busy clinicians in the field of hematology and oncology.
All articles published by Experimental Hematology and Oncology are made freely and permanently accessible online immediately upon publication, without subscription charges or registration barriers. Further information about open access can be found here.
Authors of articles published in Experimental Hematology and Oncology are the copyright holders of their articles and have granted to any third party, in advance and in perpetuity, the right to use, reproduce or disseminate the article, according to the BioMed Central copyright and license agreement.
For authors who are US government employees or are prevented from being copyright holders for similar reasons, BioMed Central can accommodate non-standard copyright lines. Please contact us if further information is needed.
Open access publishing is not without costs. Experimental Hematology and Oncology therefore levies an article-processing charge of £1295/$2205/€1640 for each article accepted for publication. If the submitting author's institution is a Member, the cost of the article-processing charge is covered by the membership, and no further charge is payable. In the case of authors whose institutions are Supporter Members, however, a discounted article-processing charge is payable by the author. We routinely waive charges for authors from low-income countries. For other countries, article-processing charge waivers or discounts are granted on a case-by-case basis to authors with insufficient funds. Authors can request a waiver or discount during the submission process. For further details, see our article-processing charge page.
All articles published in Experimental Hematology and Oncology are included in:
- Google Scholar
- PubMed Central
The full text of all research articles published by BioMed Central is also available on SpringerLink.
BioMed Central is working closely with Thomson Reuters (ISI) to ensure that citation analysis of articles published in Experimental Hematology and Oncology will be available.
Publication and peer review process
Criteria for publication
Experimental Hematology & Oncology considers the following types of articles:
Research: reports of data from original research.
Reviews: comprehensive, authoritative, descriptions of any subject within the journal's scope. Reviews can cover any topical themes such as basic science and clinical reviews, ethics, pro/con debates, equipment reviews and thematic series to highlight specific topics in the field.
Case reports: reports of clinical cases that can be educational, describe a diagnostic or therapeutic dilemma, suggest an association, or present an important adverse reaction. These can also be used to present unexpected or unusual images of a disease. All case report articles should indicate that informed consent to publish the information was granted from the patients or their guardians.
Letters to the Editor: brief laboratory and clinical studies should be submitted in this format for rapid communication. Reports of individual cases which may impact and /or enhance clinical practice or diagnostic understanding can also be submitted in this format. These can also take other forms: a substantial re-analysis of a previously published article, or a substantial response to such a re-analysis from the authors of the original publication, or an article that may not cover 'standard research' but that may be relevant to readers.
Rapid communications: preliminary results of significant interest that are particularly topical and relevant, and for which fast publication is essential.
Experimental Hematology & Oncology has a 'closed' peer review policy. All submitted manuscripts will be screened before being sent to two peer reviewers. The Editor-in-Chief and Associate Editors are routinely involved in decision-making, but final decisions lie with the Editor-in-Chief. The journal aims to reach a first decision within six weeks. If an author has queries or is unhappy with a decision, there will be a discussion involving the Editor-in-Chief and at least one of the Associate Editors who were not involved in the initial reviewing.
Edited by Delong Liu and Zihai Li, Experimental Hematology & Oncology is supported by an expert Editorial Board.
Authors will be able to check the progress of their manuscript through the submission system at any time by logging into My Experimental Hematology & Oncology, a personalized section of the site.
High-quality, bound reprints can be purchased for all articles published. Please see our reprints website for further information about ordering reprints.
Experimental Hematology and Oncology will consider supplements based on proceedings (full articles or meeting abstracts), reviews or research. All articles submitted for publication in supplements are subject to peer review. Published supplements are fully searchable and freely accessible online and can also be produced in print. For further information, please contact us.
All manuscripts submitted to Experimental Hematology and Oncology should adhere to BioMed Central's editorial policies.
Citing articles in Experimental Hematology and Oncology
Articles in Experimental Hematology and Oncology should be cited in the same way as articles in a traditional journal. Because articles are not printed, they do not have page numbers; instead, they are given a unique article number.
Article citations follow this format:
Authors: Title. Exp Hematol Oncol [year], [volume number]:[article number].
e.g. Roberts LD, Hassall DG, Winegar DA, Haselden JN, Nicholls AW, Griffin JL: Increased hepatic oxidative metabolism distinguishes the action of Peroxisome Proliferator-Activated Receptor delta from Peroxisome Proliferator-Activated Receptor gamma in the Ob/Ob mouse. Exp Hematol Oncol 2009, 1:115.
refers to article 115 from Volume 1 of the journal.
Why publish your article in Experimental Hematology and Oncology?
Experimental Hematology and Oncology's open access policy allows maximum visibility of articles published in the journal as they are available to a wide, global audience. Articles that have been especially highly accessed are highlighted with a 'Highly accessed' graphic, which appears on the journal's contents pages and search results.
Speed of publication
Experimental Hematology and Oncology offers a fast publication schedule whilst maintaining rigorous peer review; all articles must be submitted online, and peer review is managed fully electronically (articles are distributed in PDF form, which is automatically generated from the submitted files). Articles will be published with their final citation after acceptance, in both fully browsable web form, and as a formatted PDF; the article will then be available through Experimental Hematology and Oncology and BioMed Central.
Online publication in Experimental Hematology and Oncology gives authors the opportunity to publish large datasets, large numbers of color illustrations and moving pictures, to display data in a form that can be read directly by other software packages so as to allow readers to manipulate the data for themselves, and to create all relevant links (for example, to PubMed, to sequence and other databases, and to other articles).
Promotion and press coverage
Articles published in Experimental Hematology and Oncology are included in article alerts and regular email updates. Some may be included in abstract books mailed to academics and are highlighted on Experimental Hematology and Oncology's pages and on the BioMed Central homepage.
In addition, articles published in Experimental Hematology and Oncology may be promoted by press releases to the general or scientific press. These activities increase the exposure and number of accesses for articles published in Experimental Hematology and Oncology. A list of articles recently press-released by journals published by BioMed Central is available here.
Authors of articles published in Experimental Hematology and Oncology retain the copyright of their articles and are free to reproduce and disseminate their work (for further details, see the BioMed Central copyright policy and license agreement).
For further information about the advantages of publishing in a journal from BioMed Central, please click here.